QCG
MIRM icon

Quadrant Capital Group’s Mirum Pharmaceuticals MIRM Stock Holding History

Quadrant Capital Group’s Portfolio MIRM Stock Details MIRM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-31
Closed -$2.86K – 2036
2026
Q1 		$2.86K Hold
31
– – ﹤0.01% 2458
2025
Q4 		$2.45K Hold
31
– – ﹤0.01% 2483
2025
Q3 		$2.27K Buy
+31
New +$1.97K ﹤0.01% 2451
2025
Q2 		– Sell
-117
Closed -$5.27K – 2096
2025
Q1 		$5.27K Hold
117
– – ﹤0.01% 2343
2024
Q4 		$4.84K Buy
+117
New +$4.88K ﹤0.01% 2308

Other funds holding MIRM

FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Quadrant Capital Group's MIRM Position: Q2 2026 in Review

Quadrant Capital Group sold out of Mirum Pharmaceuticals (MIRM) in Q2 2026, closing a stake of 31 shares — an estimated $2.86K sold.

Quadrant Capital Group first reported a position in MIRM in Q4 2024 and held it in 5 quarters. The position peaked at $5.27K in Q1 2025. 327 funds tracked by Wall St. Rank hold MIRM as of Q2 2026.

  • Quadrant Capital Group reported no remaining Mirum Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Quadrant Capital Group sold 31 Mirum Pharmaceuticals shares in Q2 2026, an estimated $2.86K.
  • Quadrant Capital Group first reported a position in Mirum Pharmaceuticals in Q4 2024 and held it in 5 quarters.
  • Quadrant Capital Group's Mirum Pharmaceuticals position peaked at $5.27K in Q1 2025.
  • 327 funds tracked by Wall St. Rank held Mirum Pharmaceuticals as of Q2 2026.

Based on Quadrant Capital Group's 13F filing for Q2 2026, filed 14 Aug 2026.